Milnacipran, also known as milnacipranhydrochloride or Savella, helps to alleviate thepain caused by fibromyalgia through blocking thereuptake of serotonin and norepinephrine. Duringtwo double-blind clinical trials, Milcanipran hasbeen shown to decrease pain experienced bypatients with fibromyalgia by as much as 30percent. Furthermore, patients reporting the mostimprovement benefitted from the drug in as littleas one week after initiating treatment.
Currently marketed by Forest Laboratories,Milnacipran was developed by CypressBiosciences, Inc., with support from physician andpharmaceutical investor Lindsay Rosenwald, MD,who co-founded Opus Point Partners, CougarBiotechnologies, Inc., and numerous othercompanies. Aided by his decades of experience inthe pharmaceutical industry, Dr. LindsayRosenwald played a major role in gaining FDAapproval for Milnacipran in 2009, and has securedapproval for the marketing of drugs for thetreatment of leukemia, prostate cancer, obesity,and rheumatoid arthritis as well.
For more information on Milnacipran and CypressBioscience, visit www.cypressbio.com.